ClinicalTrials.gov
ClinicalTrials.gov Menu

Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00815594
Recruitment Status : Unknown
Verified December 2008 by Capital Medical University.
Recruitment status was:  Active, not recruiting
First Posted : December 30, 2008
Last Update Posted : December 30, 2008
Sponsor:
Information provided by:
Capital Medical University

December 29, 2008
December 30, 2008
December 30, 2008
December 2008
March 2009   (Final data collection date for primary outcome measure)
bleb vascular change [ Time Frame: one day, one week, one month ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Bleb Vascularity Change After Subconjunctival Injection Bevacizumab
Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab
The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Bleb Vascularity
  • Conjunctival Scarring
Drug: bevacizumab
0.05ml, 1.25mg
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
30
Same as current
May 2009
March 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Glaucoma patients after trabeculectomy whose bleb is hyperaemia

Exclusion Criteria:

  • Affected eye has normal IOP
  • Not allergic with Avastin
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT00815594
2008TR-LX-001
Yes
Not Provided
Not Provided
Wang NingLi, Beiing Tongren hospital
Capital Medical University
Not Provided
Principal Investigator: Liu Xuan, M.D. An ophthalmologist in Tongren hospital
Capital Medical University
December 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP